Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Twitter may be worth only a third of its pre-Musk value, Fidelity says
Now even Zoom tells staff: ‘Come back to the office’
Ford Takes $3.6 Billion Hit for Following the Tesla Playbook
Twitter threatens to sue Meta after rival app Threads gains traction
FTX sues founder Bankman-Fried's parents
US Considers Limits on Cloud Computing For China
Marvel Snap May 16 Patch Notes: Full List of Changes
Scientists discover fluffy 'alien' planet where it rains sand